These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34761312)

  • 1. The lessebo effect in randomized controlled trials of rituximab in patients with rheumatoid arthritis: a meta-analysis.
    Sung YK; Lee YH
    Z Rheumatol; 2023 Jan; 82(Suppl 1):44-50. PubMed ID: 34761312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
    Bae SC; Lee YH
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis.
    Lopez L; Griffier R; Barnetche T; Lhomme E; Kostine M; Truchetet ME; Schaeverbeke T; Richez C
    Rheumatology (Oxford); 2022 Feb; 61(2):531-541. PubMed ID: 34382085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
    Lee YH; Bae SC; Song GG
    Rheumatol Int; 2011 Nov; 31(11):1493-9. PubMed ID: 20473756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis of rituximab combined with methotrexate versus methotrexate alone in the treatment of rheumatoid arthritis.
    Wang Z; Bao HW; Ji Y
    Medicine (Baltimore); 2020 Feb; 99(8):e19193. PubMed ID: 32080104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Lee YH; Song GG
    Clin Drug Investig; 2020 Jan; 40(1):65-72. PubMed ID: 31602572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials.
    Huang Y; Fan Y; Liu Y; Xie W; Zhang Z
    Clin Rheumatol; 2019 Oct; 38(10):2765-2776. PubMed ID: 31087226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naïve or tumor necrosis factor inhibitor inadequate responders.
    Wu D; Hou SY; Zhao S; Hou LX; Jiao T; Xu NN; Zhang N
    Clin Rheumatol; 2019 Oct; 38(10):2747-2756. PubMed ID: 31165341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.
    Wells AF; Curtis JR; Betts KA; Douglas K; Du EX; Ganguli A
    Clin Ther; 2017 Aug; 39(8):1680-1694.e2. PubMed ID: 28734661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents.
    Migliore A; Bizzi E; Petrella L; Bruzzese V; Cassol M; Integlia D
    BioDrugs; 2016 Apr; 30(2):105-15. PubMed ID: 26905069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities.
    Chung CP; Thompson JL; Koch GG; Amara I; Strand V; Pincus T
    Ann Rheum Dis; 2006 Dec; 65(12):1602-7. PubMed ID: 16504992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
    van Vollenhoven RF; Wax S; Li Y; Tak PP
    Arthritis Rheumatol; 2015 Nov; 67(11):2828-36. PubMed ID: 26137975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
    Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
    Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.